<DOC>
	<DOCNO>NCT02135302</DOCNO>
	<brief_summary>This multi-center , open-label clinical study ass single-dose PK eravacycline subject hepatic impairment healthy subject conduct approximately 3 site United States . This study include 21-day Screening Period , 5-day Treatment Period , End Study Visit occur approximately 2 week ( ± 2 day ) initiation study drug administration . Approximately 24 subject enrol : 18 subject impaired hepatic function ( 6 subject meet criterion 3 Child-Pugh category mild [ 5 - 6 point ] , moderate [ 7 - 9 point ] , severe [ 10 - 15 point ] ) 6 healthy subject without hepatic impairment . Healthy subject match hepatically impaired subject gender , age , body mass index ( BMI ) . All subject administer single IV dose eravacycline ( 1.5 mg/kg ) .</brief_summary>
	<brief_title>A Phase 1 , Open-Label Study Assess Single-Dose Pharmacokinetics Eravacycline Subjects With Impaired Hepatic Function Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Male female subject age ≥18 year Screening ; 2 . Eligible female subject childbearing potential nonsterilized male sexual partner must agree use 2 medically accept , effective method birth control ( eg , hormonal contraceptive , barrier contraceptive additional spermicide , intrauterine device ) begin &gt; 30 day prior study drug administration continue 7 day end study . Female subject postmenopausal must postmenopausal &gt; 1 year wish use contraceptive . If postmenopausal status questionable , subject 's folliclestimulating hormone level must check must elevate consistent postmenopausal level ( ie , &gt; 40 IU/L ) ; otherwise subject must agree use contraceptive list ; 3 . Male subject sexual partner childbearing potential must agree use barrier contraceptive time study drug administration 7 day end study ; 4 . Female subject childbearing potential ( include female questionable postmenopausal status ) must negative pregnancy test prior dose ( Screening Day 1 ) ; 5 . Has body mass index 17 kg/m2 40 kg/m2 , inclusive ; 6 . Has negative alcohol illicit drug screen ; 7 . Has negative screen Human immunodeficiency virus ( HIV ) ; 8 . Is able understand comply study procedure give write informed consent accord institutional regulatory guideline ; Subjects hepatic impairment : 9 . Has positive diagnosis liver cirrhosis stable 2 month confirm image technique , biopsy , physical sign consistent clinical diagnosis liver cirrhosis ( eg , liver firmness palpation , splenic enlargement , spider angioma , palmar erythema , parotid hypertrophy , testicular atrophy , gynecomastia ) ; 10 . Subjects hepatic impairment must categorize 1 follow : Mild hepatic impairment : impaired stable hepatic function evidence ChildPugh Clinical Assessment Score 56 Screening Day 1 ; Moderate hepatic impairment : impaired stable hepatic function evidence ChildPugh Clinical Assessment Score 79 Screening Day 1 ; Severe hepatic impairment : impaired stable hepatic function evidence ChildPugh Clinical Assessment Score 1015 Screening Day 1 ; Healthy subject without hepatic impairment : 11 . Must good health determine screen medical history , physical examination , vital sign , blood chemistry , hematology , glucose , coagulation performance Screening ; 12 . Has negative screen hepatitis B ( HBV ) hepatitis C ( HCV ) ; 13 . Should match subject hepatic impairment gender , age , BMI . 1 . Female subject pregnant , breastfeeding , plan become pregnant course study ; 2 . Has history current evidence clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , neurological , psychiatric disease may pose significant safety risk diminish subject 's ability undergo study procedures assessment ; 3 . Evidence renal impairment creatinine clearance &lt; 50 mL/min/1.73m2 measure Cockcroft Gault formula ; 4 . Use another investigational drug device within 30 day prior receive eravacycline ( TP434 ) , within least 5 halflives previous investigational drug , whichever longer ; 5 . Has history alcoholism drug abuse within 2 year prior dose ; 6 . Has typical weekly alcohol consumption 14 alcoholic drink . One drink define 1 glass beer ( approximately 10 oz 12 oz ) 1 ( 12 oz ) beer , 1 glass wine ( approximately 4 oz 5 oz ) , 1 glass distil spirit ( hard liquor ) contain 1 oz liquor ( 1 oz liquid approximately 30 mL ) ; 7 . Use alcohol within 48 hour prior dose ; 8 . Has major surgical procedure within 3 month prior administration study drug ; 9 . Has know allergy tetracycline antibiotic related compound , history multiple adverse drug allergy origin ; 10 . Has inadequate venous access ; 11 . Donated &gt; 500 mL blood within 2 month prior Screening ; 12 . Has change dose frequency new chronic doseadjusted prescription nonprescription medication , include vitamin herbal medication , within 7 day 5 halflives ( know ) , whichever longer , within 2 week prior dose ; 13 . Is member clinical site personnel directly affiliate study ; 14 . Has poor mental function reason expect subject difficulty comply requirement study judgment investigator ; 15 . Fails comply protocol requirement , whose participation study would unsuitable subject , determined investigator ; 16 . Clinically significant abnormal electrocardiogram ( ECGs ) ( QTcB QTcF &gt; 500 msec ) ; Subjects hepatic impairment : 17 . Has active HCV HBV receive antiviral therapy ( either prescribe herbal ) ; 18 . Has fluctuate rapidly deteriorate hepatic function indicate clinical and/or laboratory sign hepatic impairment ( advanced ascites , infection ascites , fever , active gastrointestinal bleeding ) ; 19 . Has sodium level 125 mmol/L ; 20 . Has platelets &lt; 40,000 × 109/L blood evidence severe active recent bleeding ; 21 . Has refractory encephalopathy , judge investigator , significant central nervous system disease ( eg , dementia seizure ) investigator considers interfere inform consent , conduct , completion , result study , constitute unacceptable risk subject ; 22 . Has sign active infection ; 23 . Has experience esophageal variceal bleeding within past 6 month ; 24 . Has Transjugular Intrahepatic Portosystemic Shunt placement ; Subjects without hepatic impairment : 25 . Has aspartate aminotransferase alanine aminotransferase &gt; 1.5 × upper limit normal ( ULN ) ; alkaline phosphatase bilirubin 1.5 × ULN ( isolated bilirubin &gt; 1.5 × ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A single repeat allow eligibility determination ; 26 . Has systolic blood pressure outside range 90160 mmHg , diastolic blood pressure outside range 45100 mmHg , heart rate outside range 50100 bpm female subject 45100 bpm male subject ; 27 . Has history Gilbert 's disease ; 28 . Takes concomitant medication , either prescribed overthecounter . This include use prescription nonprescription medication , include vitamin herbal medication , within 7 day 5 halflives ( know ) , whichever longer , prior dose within 24 hour dose , exclude hormonal contraceptive . The use acetaminophen , naproxen , ibuprofen permit except within 24 hour prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>hepatic</keyword>
</DOC>